On October 3, 2024, BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) registered a Phase I clinical trial for BG-C137, an antibody-drug conjugate (ADC) for the treatment of advanced solid tumors, on ClinicalTrials.gov. The trial plans to enroll 68 patients with advanced solid tumors and is expected to be completed by the end of 2026.
BeiGene has established its own ADC technology platform. BG-C137 is an ADC targeting FGFR2b, with a payload consisting of a TOPOI inhibitor. It features a drug-antibody ratio (DAR) of 8 and utilizes a stable linker to avoid corneal toxicity.
ADCs have become a key focus in BeiGene’s pipeline, with candidates targeting B7H3, B7H4, CEA, FGFR2b, and others entering clinical stages. These cover a range of major oncology indications, including lung, breast, and gastrointestinal tumors.- Fineline.com
